|
IQVIA™ Real-World Insights Bibliography
| Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. |
| Author(s): Emery P1, Gottenberg JE2, Rubbert-Roth A3, Sarzi-Puttini P4, Choquette D5, Taboada VM6, Barile-Fabris L7, Moots RJ8, Ostor A9, Andrianakos A10, Gemmen E11, Mpofu C12, Chung C13, Gylvin LH12, Finckh A14. |
| Affiliations(s): 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
2Department of Rheumatology, CHU Strasbourg, Strasbourg, France.
3University of Cologne, Cologne, Germany.
4L Sacco University Hospital, Milan, Italy.
5University of Montreal, Montreal, Canada.
6Facultad de Medicina, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain.
7Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México City, Mexico.
8Department of Rheumatology, University of Liverpool, Liverpool, UK.
9Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
10Hellenic Foundation for Rheumatological Research, Athens, Greece.
11Quintiles, Rockville, Maryland, USA.
12F Hoffmann-La Roche Ltd, Basel, Switzerland.
13Genentech Inc, San Francisco, California, USA.
14University Hospital of Geneva, Geneva, Switzerland. |
Publication(s): Ann Rheum Dis. 2015 Jun;74(6):979-84
|
| Document Type(s): Article, |
| Countries: Canada, Colombia, France, Germany, Greece, Italy, Mexico, Norway, Portugal, Spain, UK, |
| Click here for the abstract |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment, Rheumatology,
2015 |
|
L:
A: |
English
Clinical setting: hospital, clinical setting: Secondary care, Prospective study, RWLPR (Real-World Late Phase Research-quintiles, |
|
 |
| |
| |
| Cost-effectiveness of bendamustine versus fludarabine for first-line treatment of chronic lymphocytic leukemia (cll) in Colombia |
| Author(s): Bertwistle D1, Munakata J2, Wehler E3, Leyva V4, Ariza JG5, Zambrano C5, Gonzalez L6 |
| Affiliations(s): 1IMS Health, London, United Kingdom, 2IMS Health, San Francisco, CA, USA, 3IMS Health, Alexandria, VA, USA, 4IMS Health, Mexico City, Mexico, 5Janssen Cilag, Bogotá, Colombia, 6Janssen, Raritan, NJ, USA |
Publication(s): ISPOR 16th Annual European Congress, 2013. PCN119.
|
| Document Type(s): Abstract, Poster, |
| Countries: Colombia, |
C:
Y: |
Oncology,
2013 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
| The cost-effectiveness of bendamustine-rituximab versus fludarabine-rituximab for patients with indolent non-hodgkin's lymphoma (inhl) who have progressed following treatment with rituximab or a rituximab-containing regimen in Colombia |
| Author(s): Bertwistle D1, Munakata J2, Wehler E3, Leyva V4, Ariza JG5, Zambrano C5, Gonzalez L6 |
| Affiliations(s): 1IMS Health, London, United Kingdom, 2IMS Health, San Francisco, CA, USA, 3IMS Health, Alexandria, VA, USA, 4IMS Health, Mexico City, Mexico, 5Janssen Cilag, Bogotá, Colombia, 6Janssen, Raritan, NJ, USA |
Publication(s): ISPOR 16th Annual European Congress, 2013. PCN94.
|
| Document Type(s): Abstract, Poster, |
| Countries: Colombia, |
C:
Y: |
Oncology,
2013 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
| Cost-effectiveness analysis of indacaterol versus fixed-dose combinations (formoterol + budesonide and salmeterol + fluticasone) for patients with COPD in Colombia. |
| Author(s): Ariza JG1, Thuresson P2, Machnicki G3, Mungapen L4, Kraemer M5, Asukai Y4, Giraldo L6 |
| Affiliations(s): 1Novartis, Colombia; 2IMS Health, Switzerland; 3Novartis Latin America and Canada; 4IMS Health, UK; 5Novartis Pharma AG, Switzerland; 6Clinica Universidad de La Sabana, Colombia |
Publication(s): www.htai2012.org/
|
| Document Type(s): Poster, |
| Countries: Colombia, |
C:
Y: |
Respiratory disease,
2012 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
| The cost-effectiveness and budget impact of introducing Indacaterol into the Colombian health system |
| Author(s): Mungapen L1 |
| Affiliations(s): 1 IMS Health, London, UK |
Publication(s): Value in Health, Latin America
|
| Document Type(s): Article, |
| Countries: Colombia, |
C:
Y: |
Respiratory disease,
2012 |
|
L:
A: |
English
Budget impact, Cost effectiveness, |
|
|
| |
| |
| Cost-effectiveness of Rivaroxaban versus Enoxaparin for Thromboprophylaxis after total hip replacement or total knee replacement in Colombia |
| Author(s): Pereira R1, Duran A2, Lindner L3, Toro W4, Arango CH5 |
| Affiliations(s): 1IMS Health, Lisbon, Portugal, 2IMS Health, London, United Kingdom, 3IMS Health, Barcelona, Spain, 4Bayer Schering Pharma, Bogotá, Colombia, 5Synergia Consultoría y Gestión S.A, Bogotá D.C, Colombia |
Publication(s): ISPOR 2nd Latin America Conference (10-12 September 2009), Rio de Janeiro, Brazil
|
| Document Type(s): Abstract, |
| Countries: Colombia, |
C:
Y: |
Cardiovascular disease,
2009 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
|
|
|
